0 Articles
0 News
0 Properties
0 Page
0 Blog


iBio and CC-Pharming Hold Design, Strategy Meeting

NEW YORK, Oct. 02, 2018 (GLOBE NEWSWIRE) -- iBio, Inc. (NYSE AMERICAN:IBIO) today announced the beginning of a four-day design and strategic planning meeting with executives and technical experts from CC-Pharming Ltd of Beijing China at iBio’s development and manufacturing facility in Bryan Texas. The meeting initiates the first stage of the companies’ business collaboration and will include work on product, process, and facility design for a monoclonal therapeutic antibody product: a plant-derived, bio-better rituximab.
The therapeutic antibody is the first product focus of a Master Joint Development Agreement executed in July between iBio and CC-Pharming. iBio will provide process development and manufacturing services at its Texas facility for initial product development, and will assist CC-Pharming in facility design and optimization for eventual manufacturing in China. CC-Pharming will manage all operations in China, with iBio participating through joint ownership of the China business and ongoing collaboration.
“We are excited to begin the operational aspects of our collaboration with CC-Pharming,” said Robert Kay, iBio’s Chairman and CEO. “We have a shared vision to bring significant product benefits of iBio’s technology and capabilities, combined with those of CC-Pharming, to the people of China and to expand our work with CC-Pharming to achieve solid commercial success for both companies.”
For more on the partnership for this Brazos Valley business, click here.